To determine where pharma/biopharma regulatory functions see the greatest potential for AI technology, ArisGlobal commissioned an exclusive survey1 of senior regulatory professionals in US pharma and biopharma organisations. The research was conducted in early September 2024. Discussing the findings, Renato Rjavec from ArisGlobal notes that, although plans to invest in regulatory AI solutions are high, many companies […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!